You are here
Naureen StarlingNew ESMO clinical practice guidelines on gastric cancer were published in 2016. Dr Starling takes the audience on a journey that addresses: the advances in chemotherapy treatments over the past 2 decades, the impact of targeted therapies, and the relatively new area of checkpoint inhibitors. She summarises many of the negative clinical trial results and highlights emerging areas of clinical research in advanced/metastatic gastric and gastroesophageal junction (GEJ) cancer.
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al.Ann Oncol 2016;27:2196-2203.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran, et al.Br J Cancer 2016;115:974-982.
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
Davidson M, Smyth EC, Cunningham D.Onco Targets Ther 2016;9:4539–48.
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka SAnn Oncol 2016 Jan 7. pii: mdv625. [Epub ahead of print]
Quality-of-life and performance status results from the phase 3 RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
Al-Batran SE, Van Cutsem E, Cheul Oh S, Bodoky G, Shimada Y, Hironaka S, et al.Ann Oncol. 2016 Jan 7 [Epub ahead of print]
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.Gastric Cancer. 2015 Oct 28. [Epub ahead of print]